Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis
| Autor: | Henrik Simonsen, Jhinuk Basu Mullick, Rikke Elgaard Clausen, Lise Larsen, Morten A. Karsdal, Diana Julie Leeming, Natasha Barascuk, Efstathios Vassiliadis, Toni Segovia-Silvestre, Sanne Skovgård Veidal, Anne-Christine Bay-Jensen, Dorthe Vang Larsen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Enzyme-Linked Immunosorbent Assay
Dermatology Matrix (biology) MMP9 Bleomycin Skin Diseases Epitope Extracellular matrix chemistry.chemical_compound Collagen Type III Epitopes Mice Fibrosis medicine lcsh:Dermatology Animals Mice Inbred C3H lcsh:RL1-803 medicine.disease Molecular biology Extracellular Matrix chemistry Matrix Metalloproteinase 9 Biomarker (medicine) Female Biomarkers Research Article |
| Zdroj: | BMC Dermatology BMC Dermatology, Vol 11, Iss 1, p 6 (2011) |
| ISSN: | 1471-5945 |
| Popis: | Background The current study utilized a Bleomycin-induced model of skin fibrosis to investigate the neo-epitope CO3-610 (KNGETGPQGP), a fragment of collagen III released during matrix metalloproteinase-9 (MMP9) degradation of the protein, we have previously described as a novel biomarker for liver fibrosis. The aim was to investigate CO3-610 levels in another well characterised model of fibrosis, to better describe the biomarker in relation to additional fibrotic pathologies. Methods Skin fibrosis was induced by daily injections of Bleomycin to a total of 52 female C3 H mice, while control mice (n = 28) were treated with phosphate buffered saline (PBS), for 2, 4, 6 or 8 weeks. Skin fibrosis was evaluated using Visiopharm software on Sirius-red stained skin sections. Urine ELISA assays and creatinine corrections were performed to measure CO3-610 levels. Results CO3-610 levels were significantly higher in Bleomycin-treated vs. PBS-treated mice at each time point of termination. The mean increases were: 59.2%, P < 0.0008, at 2 weeks; 113.5%, P < 0.001, at 4 weeks; 136.8%, P < 0.0001 at 6 weeks; 157.2%, P < 0.0001 at 8 weeks). PBS-treated mice showed a non-significant increase in CO3-610 levels (mean increase for weeks 2-8 = 1.7%, P = 0.789) CO3-610 levels assayed in urine were statistically significantly correlated with Western blot analysis showing increased skin fibrosis (P < 0.0001, r = 0.65). Conclusion Increased levels in mouse urine of the MMP-9 mediated collagen III degradation fragment CO3-610 were correlated with skin fibrosis progression, suggesting that CO3-610 may be a potential positive biomarker to study the pathogenesis of skin fibrosis in mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink